Literature DB >> 16648037

Rituximab for early-stage diffuse large-B-cell lymphoma.

Jonathan W Friedberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648037     DOI: 10.1016/S1470-2045(06)70668-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Non-Hodgkin's lymphoma in the elderly.

Authors:  Paolo F Caimi; Paul M Barr; Nathan A Berger; Hillard M Lazarus
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

2.  Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.

Authors:  Amro Mohamed Sedky El-Ghammaz; Hoda Ahmed Gadallah; Gihan Kamal; Mohammed Magdy Maher; Mohamad Ayed Mohamad
Journal:  Clin Exp Med       Date:  2018-06-06       Impact factor: 3.984

3.  Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.

Authors:  Yang Zhao; Hui Xu; Mingzhi Zhang; Ling Li
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

4.  Pathophysiology and molecular aspects of diffuse large B-cell lymphoma.

Authors:  Gisele Rodrigues Gouveia; Sheila Aparecida Coelho Siqueira; Juliana Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

5.  Double hit lymphoma - a case of unusual response after sequential aggressive chemotherapy and review of the literature.

Authors:  Faisal N Cheema; Maliha Agloria; Nebu Koshy; Gerhard C Hildebrandt
Journal:  Clin Med Insights Case Rep       Date:  2014-10-01

6.  Trial watch: Chemotherapy with immunogenic cell death inducers.

Authors:  Erika Vacchelli; Laura Senovilla; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.